Ovagen
Ovagen HomeCompanyInvestorsContact
Ovagen
  Investor relations  
Ovagen   Ovagen
 
Ovagen Ovagen Ovagen Ovagen Ovagen

INVESTOR INFORMATION

Ovagen was established in 2000 as a privately funded R&D company.

Ovagen Group Limited is a privately owned company incorporated in the Republic of Ireland.

There are two wholly owned subsidiaries:
• Ovagen International Ltd. (Patent holding company)
• Ovagen Ltd., (Principle trading company).

 

UPDATES

If you would like to be notified of updates and progress relating to Ovagen, please enter your email address below. Your email address will not be passed on to any third party companies.

Ovagen

PRODUCT ROADMAP

2000
Concept defined, independent market research and initial investment

Ongoing R&D

2005
Proof of concept (2 genetic lines, >60% hatchability at first derivation to >80% in subsequent generations, fully sustainable breeding cycle)

2006
First press release to coincide with World Vaccine Congress 2006 in Lyon

2007
Extensive market research with large multinational phamaceutical companies confirms value proposition and market size.
Site acquired for new facilities
Detailed design and planning application for Phase I building.
New private investor funding.

2008
Secure investment from external financing/institutional investment for full scale manufacturing and 'go-to-market' strategy. Round I funding for €8m was completed in April.
Phase I planning application approved. Construction starts.
Detailed design of manufacturing facilities completed.
Planning application granted for all commercial production facilities.

2009
Total funding raised to date increases to €12m
Awarded EU Framework 7 funding for work on isolation of bone marrow stem cells (www.purstem.eu)

2010
Funding to date increases to €12.6m.
Establishment of transgenic laboratory facilities

2011
Establishment of first transgenic chicken line expresing recombinant antibody for purification of stem cells.

2012
Identification of strategic partners and completion of funding round Establish new foundation flocks. Development of contract research business.

2013
Commercialisation of Germ Free business. Customer validation of GF eggs/cells. First sales of GF eggs

2014
Expansion of Germ Free business.

2015
Rapidly expanding production and sales of GF eggs direct to pharmaceutical companies.

Ovagen
Total Funding
Ovagen

NEW FACILITIES

Ovagen

New Facilities (2500msq)

  • First generation germ-free flocks
  • Isolators, Incubators
  • Laboratories
  • Pilot scale (25%) commercial production
  • R&D
  • Head Office

Lower Floor Provides:

  • SPF flocks
  • Large Germ-Free (GF) Isolators
  • GF suite for flock of 1000 birds
  • GF 'space' suits & decontamination showers
  • GF feed handling
  • GF egg collection & packaging

Upper Floor Provides:

  • SPF showers
  • Incubating/Hatching Isolators
  • Transport Isolators
  • Laboratories & QA
  • Head Offices
  • Site BMS & IT facilities

Ovagen Ovagen Ovagen Ovagen Ovagen
 
Ovagen   Ovagen
Ovagen Ovagen
Copyright 2016. New Replica Watches For Sale UK © 2016 | rolex replica - hublot replica - replica watches sale